Actively Recruiting

Age: 18Years +
All Genders
NCT06899789

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

Led by Fondazione IRCCS Policlinico San Matteo di Pavia · Updated on 2025-03-28

250

Participants Needed

1

Research Sites

230 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multicentric, observational study, including all European centres willing to take part. The multicentre nature is necessary for enhancing the generalisability of our results, and due to the rarity of this condition. The study is observational including both retrospective and newly diagnosed cases of CIC with an endoscopically/histologically-proven diagnosis. Detailed characteristics will be collected, with the aim of classifying the disorders from a clinical, endoscopic, and pathological point of view. Age, sex, localisation, and histology of tumour, stage of tumour, oncological response to immune checkpoint inhibitors-induced colitis, colonoscopy, histology, inflammatory parameters, and clinical manifestations will be assessed for each patient, as well as therapy and outcome. The study will consist of 2 part: the first one will be retrospective, while the second one will be prospective al will include all incident patients diagnosed with CIC during the enrolment period.

CONDITIONS

Official Title

Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Ability to provide informed consent or prior consent for data use in retrospective cases
  • Received at least one cycle of immune checkpoint inhibitors before intestinal symptoms
  • At least one colonoscopy showing macroscopic or histological colitis after starting immune checkpoint inhibitors
  • For retrospective patients, a follow-up of at least 12 months unless death occurred earlier
Not Eligible

You will not qualify if you...

  • Evidence of colitis or inflammatory bowel disease before starting immune checkpoint inhibitors

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

SC Medicina Generale 1, Fondazione IRCCS Policlinico san Matteo

Pavia, Pavia, Italy, 27100

Actively Recruiting

Loading map...

Research Team

M

Marco V Lenti, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here